Innovative drug to treat obesity and overweight arrives in Brazil

One of the main benefits of Belviq® is its safety, as it is not a stimulant nor a narcotic. Another benefit is that the patient continues to lose weight over time.
By: Eurofarma
 
SAO PAULO - Oct. 31, 2019 - PRLog -- rofarma, the biggest investor in innovation among Brazilian pharmaceutical companies with a global presence in 20 countries, announces the arrival of Belviq® (lorcaserin hydrochloride) in Brazil, an innovative drug against obesity and overweight.

Clinical studies have shown that after 52 weeks of treatment, almost half of lorcaserin patients lose 5% or more of their body weight, and 22% of those patients lose 10% or more of their body weight¹.

Available throughout Brazil, the product works best for weight loss and maintenance when complementing a lifestyle change – a good diet and physical activity. Being neither a narcotic nor a stimulant, Belviq® has good tolerability and therefore promotes adherence to treatment. Cardiovascular safety has also been proven by clinical studies – the rate of cardiovascular events with drug use was similar to the placebo group²,1.

"Belviq® further expands our solutions for combating obesity and overweight, and provides safety and convenience to doctors and their patients. The combination of effectiveness, safety and tolerability of this innovative drug helps reduce the yo-yo effect, which affects many patients suffering from this disease," said Roberta Junqueira, Commercial Director at Eurofarma.

For more information, visit https://www.eurofarma.com.br/

Contact
GEA RP
***@gaspar.com.br
End
Email:***@gaspar.com.br Email Verified
Tags:Health
Industry:Health
Location:Sao Paulo - São Paulo - Brazil
Subject:Projects
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
G&A RP News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share